The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.

被引：1
作者：
Mustacchi, Giorgio
Cazzaniga, Marina Elena
Romagnoli, Emanuela
Montemurro, Filippo
De laurentiis, Michele
Riccardi, Ferdinando
Turletti, Anna
Beano, Alessandra
De Angelis, Claudia
Graziano, Vincenzo
Livi, Lorenzo
Del Mastro, Lucia
Biganzoli, Laura
Garrone, Ornella
De Placido, Sabina
Marchetti, Paolo
Pronzato, Paolo
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1055
引用
收藏
页数：6
相关论文
共 50 条
[21]   Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study [J].
Cazzaniga, Marina Elena ;
Pronzato, Paolo ;
Amoroso, Domenico ;
Bernardo, Antonio ;
Biganzoli, Laura ;
Bisagni, Giancarlo ;
Blasi, Livio ;
Bria, Emilio ;
Cognetti, Francesco ;
Crino, Lucio ;
De Laurentiis, Michelino ;
Del Mastro, Lucia ;
De Placido, Sabino ;
Beano, Alessandra ;
Ferrau, Francesco ;
Foladore, Silva ;
Forcignano, Rosachiara ;
Gamucci, Teresa ;
Garrone, Ornella ;
Gennari, Alessandra ;
Giordano, Monica ;
Giotta, Francesco ;
Giovanardi, Filippo ;
Latini, Luciano ;
Livi, Lorenzo ;
Marchetti, Paolo ;
Mattioli, Rodolfo ;
Michelotti, Andrea ;
Montemurro, Filippo ;
Putzu, Carlo ;
Riccardi, Ferdinando ;
Ricciardi, Giuseppina ;
Romagnoli, Emanuela ;
Sarobba, Giuseppina ;
Spazzapan, Simon ;
Tagliaferri, Pierosandro ;
Tinari, Nicola ;
Tonini, Giuseppe ;
Turletti, Anna ;
Verusio, Claudio ;
Zambelli, Alberto ;
Mustacchi, Giorgio ;
Papadimitriou, Christos .
CANCERS, 2024, 16 (01)
[22]   Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study [J].
Cazzaniga, Marina Elena ;
De Placido, Sabino ;
D'Alonzo, Alessia ;
Piezzo, Michela ;
Natoli, Clara ;
Milani, Andrea ;
Bologna, Alessandra ;
Alu, Massimiliano ;
Turletti, Anna ;
Pugliese, Palma ;
Biganzoli, Laura ;
De Angelis, Claudia ;
Garrone, Ornella ;
Marchetti, Paolo ;
Riccardi, Ferdinando ;
Bernardo, Antonio ;
Livi, Lorenzo ;
Fabi, Alessandra ;
Taverniti, Cristiana ;
Romagnoli, Emanuela ;
Pronzato, Paolo ;
Mustacchi, Giorgio .
CANCER RESEARCH, 2020, 80 (04)
[23]   Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Final results of the VICTOR-6 study. [J].
Cazzaniga, Marina Elena ;
Scognamiglio, Giovanni ;
Generali, Daniele Giulio ;
Ferzi, Antonella ;
Vandone, Anna Maria ;
Spadaro, Pietro ;
Mocerino, Carmela ;
Montagna, Emilia ;
Cretella, Elisabetta ;
Gambaro, Anna ;
Taverniti, Cristiana ;
Turletti, Anna ;
Sarobba, Giuseppina ;
Iezzi, Laura ;
Roberto, Michela ;
Ciccarese, Mariangela ;
Tralongo, Paolo ;
Clivio, Luca ;
Pedroli, Stefania ;
Torri, Valter .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[24]   Lucitanib for the treatment of HR+HER2-metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial [J].
Hui, R. ;
Pearson, A. ;
Cortes Castan, J. ;
Campbell, C. ;
Poirot, C. ;
Azim, H. A., Jr. ;
Fumagalli, D. ;
Lambertini, M. ;
Daly, F. ;
Arahmani, A. ;
Perez-Garcia, J. ;
Aftimos, P. G. ;
Bedard, P. ;
Xuereb, L. ;
Loibl, S. ;
Loi, S. ;
Pierrat, M-J. ;
Turner, N. C. ;
Andre, F. ;
Curigliano, G. .
ANNALS OF ONCOLOGY, 2018, 29 :93-93
[25]   BREAKOUT: A cross-sectional, prospective, observational study of germline BRCA mutation (gBRCAm) prevalence and real-world outcomes among patients (pts) with HER2-negative (HER2-ve) metastatic breast cancer (mBC) [J].
Dalvi, T. ;
Gelmon, K. A. ;
Dent, R. ;
Pegram, M. ;
Loibl, S. ;
Tazir, Y. ;
Milner, A. ;
Lewis, J. .
ANNALS OF ONCOLOGY, 2017, 28
[26]   First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study [J].
Andreis, D. ;
Scandurra, G. ;
Santini, D. ;
Gucciardino, C. ;
La Verde, N. M. ;
Girelli, S. ;
Alabiso, I. ;
Saetta, A. ;
Atzori, F. ;
Collova, E. ;
Ferzi, A. ;
Gori, S. ;
Lipari, H. ;
Saggia, C. ;
Marcon, I. ;
Generali, D. G. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[27]   A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC) [J].
Anders, Carey ;
Le Rhun, Emily ;
Bachelot, Thomas ;
Yardley, Denise ;
Awade, Ahmad ;
Conte, Pierre Franco ;
Cabos, Peter ;
Bear, Melissa ;
Tolaney, Sarah .
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 :10-10
[28]   Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VICTOR-6 study. [J].
Cazzaniga, Marina Elena ;
Casadei, Virginia ;
Cagossi, Katia ;
Cavanna, Luigi ;
Cursano, Maria Concetta ;
De Conciliis, Enrico Maria Romano ;
Gebbia, Vittorio ;
Melegari, Elisabetta ;
Pellegrino, Benedetta ;
Pinotti, Graziella ;
Rossello, Rosalba ;
Russo, Salvatore ;
Ortu, Salvatore ;
Saracchini, Silvana ;
Stocchi, Lucia ;
Toniolo, Davide ;
Scognamiglio, Giovanni ;
Valerio, Maria Rosaria ;
Vandone, Anna Maria ;
Clivio, Luca .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[29]   A double blind phase 3 trial of fulvestrant with placebo or palbociclib in pre- and post-menopausal women with hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (PALOMA 3): Detailed analysis of patient-reported outcomes [J].
Harbeck, N. ;
Cristofanilli, M. ;
Ro, J. ;
Andre, F. ;
Loi, S. ;
Verma, S. ;
Iwata, H. ;
Loibl, S. ;
Bartlett, C. Huang ;
Zhang, K. ;
Iyer, S. ;
Thiele, A. ;
Theall, K. ;
Koehler, M. ;
Turner, N. .
EUROPEAN JOURNAL OF CANCER, 2015, 51 :S270-S271
[30]   A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2-metastatic breast cancer (MBC). [J].
Anders, Carey K. ;
Le Rhun, Emilie ;
Bachelot, Thomas Denis ;
Yardley, Denise A. ;
Awada, Ahmad ;
Conte, Pier Franco ;
Kabos, Peter ;
Bear, Melissa ;
Yang, Zhengyu ;
Chen, Yanyun ;
Tolaney, Sara M. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345